OR WAIT null SECS
Contract service providers must step up their game to stay competitive in increasingly complex bio/pharma market.
The need for preclinical testing expertise is growing as molecular complexity increases.
A look at the newest innovations offers a deeper understanding of affinity ligands and their role in the future of downstream processing.
October 01, 2011
Although the European market is approximately 50% smaller than the US in terms of landmass, the population of Europe is approximately 50% larger and this presents a huge market opportunity.
Oriol Prat, Marketing Manager, and Marga Viñes Senior Product Manager, from Grifols give us a quick rundown of how business is changing and what challenges the company faces.
In a quick-fire interview, Dr Stephen Taylor, Vice President & Commercial Director at Fujifilm Diosynth Biotechnologies, looks at some of the challenges facing biologics outsourcing.
September 02, 2011
A Q&A with John Plachetka, chair, president, and CEO of POZEN, on recent industry trends.
PDUFA renewal legislation sets stage for new policies affecting revenue, resarch, and oversight.
Being aware of a forthcoming inspection or how a product was made can make a huge difference.
Internal and external Web-based communities are changing how pharma companies can innovate.
Growth and change in Brazil and Mexico offer key opportunities for the region's pharmaceutical industry.
The EU debt crisis portends of possible negative repercussions for the dose CMO industry.
The author offers perspectives on ways in which pharmaceutical companies and other stakeholders in the supply chain can confront the threat of counterfeit products, cargo theft, illegal diversion, and economically motivated adulteration.